Whole-Brain Tumor Burden Metrics with Inflammatory and Molecular Markers to Predict Postoperative Neurocognitive Decline in Glioma

Integrating Whole-Brain Tumor Burden Metrics with Inflammatory and Molecular Markers to Predict Postoperative Neurocognitive Decline in Glioma Patients -a Prospective Cohort Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06885333

Enrollment

192

Registered

2025-03-20

Start date

2016-05-01

Completion date

2024-12-01

Last updated

2025-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma, Glioma : Oligodendroglioma or Astrocytoma

Brief summary

Although surgical resection improves overall survival in patients with diffuse Low-grade gliomas (DLGG), it can also result in deterioration of neurocognitive function, which are poorly understood and lack effective predictive models. This study aims to develop a model using whole-brain tumor burden metrics, inflammatory and molecular markers for predicting high risk of neurocognitive decline (ND) postoperatively. The study involved 192 patients with left frontal DLGG. MRI data were analyzed to derive whole-brain tumor burden metrics, including tumor radiomics, whole-brain cortical thickness, myelin content, and network characteristics. postoperative inflammatory and molecular markers were collected. Postoperative follow-up neurocognitive function was assessed using the Montreal Cognitive Assessment at 3 months and 1 year. Machine learning models were constructed using Pycaret.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

1. Histopathologically proven DLGG based on 2021 WHO criteria 2. Age ≥ 18 years, 3. Karnofsky Performance Status ≥ 70%, 4. Tumor involved unilateral left frontal lobe and did not reach the central sulcus.

Exclusion criteria

1. With previous treatment before image acquisition, 2. Presenting cognitive impairment pre-operatively based on The Montreal Cognitive Assessment (MoCA) 3. Survival of less than 3 months post-surgery 4. Lack of compliance with neurocognitive assessments in 3-month and 1-year after surgery

Design outcomes

Primary

Measure	Time frame	Description
neurocognitive function was assessed using the Montreal Cognitive Assessment	3 month	p neurocognitive function was assessed using the Montreal Cognitive Assessment

Outcome results